Page 2 - Scientific Library

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab

As discussed previously in our recent Drug Discovery post, Immunotherapy is one of the central research fields for various disease treatments and also certain cancers. A major regulator of immune homoeostasis

As a regulator of the immune system, Immune checkpoints appear to be privileged targets In Drug Discovery and Immunotherapy

Over the last several years, the Immune System has appeared as a central, priority target to fight cancer and various other diseases. Currently, in cancer

PBL assay specializes in the development of IFN related research Tools. One of their most appreciated assay kit by the IFN research community is the ELISA test kit for all Human IFN Alpha subtypes (41115

PBL Assay Science, the specialists of Interferon related quality reagents, have just released 4 new unique products to be used in neutralization assays. I am pleased to introduce them in this post, in

Recently, BPS Bioscience have released a new Adenosine A2A Receptor (A2AR / ADORA2A) Functional Recombinant Cell Line for screening A2AR agonists and antagonists. An excellent means to efficiently evaluate

Recombinant CYPs are commonly used in ADME-Tox studies as in vitro tools, mostly for reaction phenotyping, enzyme inhibition screening, clearance and metabolite ID.

"Research has shown that rCYPs expressed

Sekisui XenoTech have announced the addition of Rodent Hepatocytes to their patented CryostaX® product line.

The CryostaX® in vitro drug discovery and preclinical drug development test system is continuously

In this post, I'd like to introduce the Human liver Lysosomes developed by Sekisui-Xenotech, which have opened up a new era in catabolism models. Read on to learn more, and also to download a case study

Cell-based assays, screening for pathway activation or inhibition are classically done with promoter reporter clones expressing Firefly luciferase. Brighter, more stable, more sensitive, more convenient

RNA-based CRISPR-CAS9 gene editing is a vector-free approach that is required for therapeutic perspectives. However, from a practical point of view, what appears as a major challenge to engineer primary